[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
September 2002

Intravenous Recombinant Tissue-Type Plasminogen Activator Thrombolysis in Treatment of Central Retinal Artery Occlusion

Arch Ophthalmol. 2002;120(9):1234-1236. doi:

The natural history of untreated central retinal artery occlusion (CRAO) implies a high risk of permanent blindness.1,2 The favorable outcome of intravenous thrombolysis in stroke treatment prompted us to develop an Institutional Review Board–approved pilot study of acute CRAO treatment with intravenous thrombolysis. We describe our experience with 12 patients with acute CRAO who were treated with recombinant tissue-type plasminogen activator (rtPA), following the protocol used in the national acute stroke trial.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×